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Background
The most promising strategy to detect AD in preclinical
or presymptomatic stage need specific biomarkers. In
this study we elucidated the relationship between Apo E
genotype and CSF biomarkers Ab42 and Total tau in
Alzheimer’s Disease (AD) Patients, Non AD (NAD)
patients, Neurological controls (NCs) and Healthy
Controls (HCs).
Materials and methods
In this study we included 30 HC, 30 AD patients, 40
NAD, and 46 NC from Nehru Hospital, PGIMER, Chan-
digarh, India after obtaining informed consent from all
the subjects. Apo E Genotyping was done according to
the Wenham PR etal,1991. The levels of Ab42 and total
tau were determined by ELISA kits Innogenetics,
Belgium.
Results
Our data of CSF Ab42 and tau levels in conjunction
with ε4 allele had shown specificity and sensitivity of
100% and 42.8% respectively for the detection of AD.
Ab42 and Apo E ε4 combination had shown specificity
80.8% and sensitivity 72.1 %. The ε4 allele distribution
frequency was 40% and 2.5% in AD and NAD respec-
tively, where as ε4/4 genotype and ε3/4 genotype distri-
bution was 10 % and 50 % respectively. Our data has
shown that ε4 allele in combination with Ab42 to have
better sensitivity and specificity in the diagnosis of AD.
AD patients with at least one ε4 allele had significantly
lower CSF Ab42 levels than those without ε4a l l e l e
(P < 0.001). There was a positive correlation of Ab42
with low MMSE scores.
Conclusions
Observation from our study suggest that decreased
Ab42 and increased tau level in CSF along with Apo E
ε4 allele as risk factors for AD. Our study also shows ε4
allele incidence to be a risk factor for AD.
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